

The Patent Office formulated the following groups of allegedly distinct inventions:

- I. Claims 61, 62, 64, 65, 67, 68, 70, 72 and 73 drawn to a method for isolating γ -secretase, a protein complex having γ -secretase activity and a protein complex comprising γ -secretase;
- II. Claims 63, 66, 69 and 71, drawn to a molecule and a protein complex having γ -secretase activity;
- III. Claims 74, 75 and 81, drawn to an isolated functionally active substrate which is cleaved by γ -secretase;
- IV. Claims 76-79, drawn to a method for cleaving a functionally active substrate;
- V. Claims 80, and 82-86, drawn to a method for isolating a functionally active γ -secretase substrate;
- VI. Claims 87-91 and 95, drawn to a method for identifying an agent of interest that inhibits γ -secretase;
- VII. Claim 96, drawn to a method for isolating an integral membrane protein; and
- VIII. Claim 97, drawn to an integral membrane protein.


Applicants provisionally elect **Group VII**, which includes **claim 96**. Applicants specifically reserve the right to file one or more additional applications directed to non-elected subject matter.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880. Furthermore, if any extension of time is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to Deposit Account Number 19-3880.

If any small matter should remain outstanding after the Examiner has had an opportunity to review the above Response, the Examiner is respectfully requested to telephone the undersigned attorney in order to expeditiously resolve these matters.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575



John A. Lamerdin, Ph.D.
Attorney for Applicants
Reg. No. 44,858

Date: February 7, 2005